İsrail - İbranice - Ministry of Health

csl behring ltd., israel - c - 1 esterase inhibitor human - אבקה וממס להכנת תמיסה להזרקה - c - 1 esterase inhibitor human 3000 iu/vial - c1- inhibitor,plasma derived

İsrail - İbranice - Ministry of Health

neopharm cure (2005) ltd - c - 1 esterase inhibitor human 500 units - lyophilized powder for solution for injection - c1-inhibitor - treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (hae). routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (hae), who are intolerant to or insufficiently protected by oral prevention treatments, or patients who are inadequately managed with repeated acute treatment.

İsrail - İbranice - Ministry of Health

cts ltd - ferrous as iron iii hydroxide sucrose complex - תמיסה להזרקה - ferrous as iron iii hydroxide sucrose complex 20 mg/ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - severe iron deficiency only when oral administration has been found impossible. in cases of gastro-intestinal malobsorption which rules out oral therapy, patients on dialysis treated with erythropoietin.

İsrail - İbranice - Ministry of Health

cts ltd - ferrous as iron iii hydroxide sucrose complex - תמיסה להזרקה - ferrous as iron iii hydroxide sucrose complex 100 mg / 5 ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - severe iron deficiency only when oral administration has been found impossible. in cases of gastro-intestinal malobsorption which rules out oral therapy, patients on dialysis treated with erythropoietin.

İsrail - İbranice - Ministry of Health

lapidot medical import and marketing ltd - iron sucrose - תמיסה להזרקה - iron sucrose 20 mg/ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - severe iron deficiency only when oral administration has been found impossible. in cases of gastro- intestinal malobsorption which rules our oral therapy, patients on dialysis treated with erythropoietin.

İsrail - İbranice - Ministry of Health

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

İsrail - İbranice - Ministry of Health

organon pharma israel ltd., israel - carbidopa as monohydrate; levodopa - טבליות בשחרור מבוקר - levodopa 200 mg; carbidopa as monohydrate 50 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - idiopathic parkinson's disease. postencephalitic parkinsonism. symptomatic parkinsonism. to reduce "off" time in patients previously treated with levodopa/decarboxylase inhibitor preparations, or with levodopa alone, who have had motor fluctuations characterized by end-of-dose deterioration ("wearing-off" phenomenon), peak dose dyskinesias, akinesia, or similar evidence of short-duration motor disturbances.

İsrail - İbranice - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - bortezomib as mannitol boronic ester - אבקה להכנת תמיסה לזריקה - bortezomib as mannitol boronic ester 3.5 mg - bortezomib

İsrail - İbranice - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

İsrail - İbranice - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.